Overview

the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient

Status:
Unknown status

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

This study was a multi-center, open, randomized-control study on the effects and safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on the overall survival rate and disease-free survival rate of acute myeloid leukemia patient in high-risk group over a period of 2 years.

Phase:

Phase 3

Details

Lead Sponsor:

Guangxi Medical University

Treatments:

Busulfan
Cyclophosphamide
Cyclosporine
Cyclosporins
Idarubicin
Methotrexate
Mycophenolate mofetil
Mycophenolic Acid